0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > ErbB4

ErbB4

Brief Information

Name:Receptor protein-tyrosine kinase erbB-4
Target Synonym:EC 2.7.10,EC:2.7.10.1,ERBB4,Tyrosine kinase-type cell surface receptor HER4,s80HER4,p180erbB4,Receptor tyrosine-protein kinase erbB-4,4ICD,E4ICD,HER4,Erb-B2 Receptor Tyrosine Kinase 4,V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 4,Human Epidermal Growth Factor Receptor 4,Proto-Oncogene-Like Protein C-ErbB-4,V-Erb-A Avian Erythroblastic Leukemia Viral Oncogene Homolog-Like 4,Avian Erythroblastic Leukemia Viral (V-Erb-B2) Oncogene Homolog 4,V-Erb-A Erythroblastic Leukemia Viral On
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Approved

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
ER4-H5251 Human Human ErbB4 / Her4 Protein, Fc Tag
ER4-H5251-structure
ER4-H5251-sds
ER4-H5221 Human Human ErbB4 / Her4 Protein, His Tag
ER4-H5221-structure
ER4-H5221-sds
ACRO Quality

Part of Bioactivity data

ER4-H5221-ELISA
 ErbB4 ELISA

Immobilized Human ErbB4, His Tag (Cat. No. ER4-H5221) at 2 μg/mL (100 μL/well) can bind Human NRG1 Beta 1, Fc Tag, premium grade (Cat. No. NR1-H5268) with a linear range of 0.5-8 ng/mL (QC tested).

ER4-H5251-ELISA
 ErbB4 ELISA

Immobilized Human ErbB4, Fc Tag (Cat. No. ER4-H5251) at 2 μg/mL (100 μL/well) can bind Human NRG1-beta 1 Protein with a linear range of 0.6-10 ng/mL (Routinely tested).

Synonym Name

HER4,ErbB4,MGC138404,p180erbB4

Background

Receptor tyrosine-protein kinase erbB-4 (ErbB4), also known as Her4, is a single-pass type I transmembrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. ErbB4 is expressed in normal skeletal muscle, heart, pituitary, brain and several breast carcinomas. ERBB4 contains multiple furin-like cysteine rich domains, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is activated by neuregulins-2 and -3, heparin-binding EGF-like growth factor and betacellulin. Ligand binding induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment. ErbB4 appears to play important roles in neuronal development, development of the heart and cancer. ERBB4 has been shown to interact with: DLG4, NRG1, STAT5A, and YAP1. Mutations in this gene have been associated with cancer. Other single-nucleotide polymorphisms and a risk haplotype have been linked to schizophrenia.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Neratinib Maleate CAN-030; PB-272; HKI-272; PF-0528767; WAY-179272 Approved Pfizer Inc Nerlynx, 贺俪安 United States Breast Neoplasms Puma Biotechnology Inc 2017-07-17 Solid tumours; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung Details
Pyrotinib Maleate HTI-1001; SHR-1258; BLTN Approved Jiangsu Hengrui Medicine Co Ltd 艾瑞妮 Mainland China Breast Neoplasms Jiangsu Hengrui Medicine Co Ltd 2018-08-12 Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma of Lung; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Lung Neoplasms; Metastatic breast cancer; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Dacomitinib PF-00299804-03; PF-00299804-3; PF-00299804; PF-299804; PF-299; PF-804 Approved Pfizer Inc Vizimpro United States Carcinoma, Non-Small-Cell Lung Pfizer Inc 2018-09-27 Brain Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Penile Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Lung Neoplasms; Colorectal Neoplasms; Solid tumours; Liver Diseases; Carcinoma, Large Cell; Glioblastoma; Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Head and Neck Neoplasms Details
Osimertinib Mesylate AZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291 Approved Astrazeneca Plc 泰瑞沙, Tagrisso United States Carcinoma, Non-Small-Cell Lung Astrazeneca Pharmaceutical Co Ltd 2015-11-13 Uterine Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Meningeal Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Adenocarcinoma of Lung; Endometrial Neoplasms; Thyroid Neoplasms; Carcinoma, Squamous Cell; Lymphoma; Glioma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Adenocarcinoma; Melanoma; Esophageal Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Neoplasm, Residual; Ovarian Neoplasms; Hematologic Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Rectal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Neoplasms; Glioblastoma; Colonic Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Skin Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms Details
Afatinib Dimaleate BIBW-2992-MA2; BIBW-2992 Approved C.H. Boehringer Sohn Ag & Co. Kg Gilotrif, Giotrif, Tovok, 吉泰瑞, Tomtovok United States Carcinoma, Non-Small-Cell Lung C.H. Boehringer Sohn Ag & Co. Kg 2013-07-12 Esophageal Squamous Cell Carcinoma; Urethral Neoplasms; Brain Neoplasms; Prostatic Neoplasms; Ureteral Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Squamous Cell; Breast Neoplasms; Gallbladder Neoplasms; Uterine Neoplasms; Lymphoma; Glioma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Neoplasm Metastasis; Small Cell Lung Carcinoma; Head and Neck Neoplasms; Solid tumours; Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Renal Insufficiency; Neoplasms; Rhabdomyosarcoma; Neuroectodermal Tumors; Glioblastoma; Neoplasms, Squamous Cell; Urinary Bladder Neoplasms; Chordoma; Liver Diseases; Multiple Myeloma Details
Neratinib Maleate CAN-030; PB-272; HKI-272; PF-0528767; WAY-179272 Approved Pfizer Inc Nerlynx, 贺俪安 United States Breast Neoplasms Puma Biotechnology Inc 2017-07-17 Solid tumours; Esophageal Neoplasms; Neoplasms; Breast Neoplasms; Hepatic Insufficiency; Colorectal Neoplasms; Lung Neoplasms; Brain metastases; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung Details
Pyrotinib Maleate HTI-1001; SHR-1258; BLTN Approved Jiangsu Hengrui Medicine Co Ltd 艾瑞妮 Mainland China Breast Neoplasms Jiangsu Hengrui Medicine Co Ltd 2018-08-12 Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Adenocarcinoma of Lung; Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Lung Neoplasms; Metastatic breast cancer; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Dacomitinib PF-00299804-03; PF-00299804-3; PF-00299804; PF-299804; PF-299; PF-804 Approved Pfizer Inc Vizimpro United States Carcinoma, Non-Small-Cell Lung Pfizer Inc 2018-09-27 Brain Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Penile Neoplasms; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Mouth Neoplasms; Lung Neoplasms; Colorectal Neoplasms; Solid tumours; Liver Diseases; Carcinoma, Large Cell; Glioblastoma; Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Head and Neck Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Varlitinib Ditosylate SPS-4370; ASLAN-001; ARRY-334543; ARRY-543; QBT-01 Phase 3 Clinical Array Biopharma Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms Details
Larotinib Mesylate Z-650 Phase 3 Clinical Guangdong Dongyangguang Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma Details
Tesevatinib XL-647; KD-020; KD-019; EXEL-7647 Phase 2 Clinical Exelixis Inc Glioblastoma; Neoplasms; Brain Neoplasms; Breast Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Allitinib Tosylate AST-6; ALS-1306; AST-1306 Phase 2 Clinical Shanghai Allist Pharmaceutical Technology Co Ltd Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Neratinib (Fukang (Shanghai) Health Technology) CVL009; CVL-009 Phase 2 Clinical Solid tumours; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung Details
EO-1001 NT-113; APL-122 Phase 2 Clinical Edison Pharmaceuticals Inc Neoplasms Details
JRF-103 JRF103; JRF-103 Phase 2 Clinical Shenzhen Jinrui Foundation Biotechnology Co Ltd Solid tumours Details
FCN-411 FCN-411 Phase 2 Clinical Shanghai Fosun Pharmaceutical (Group) Co Ltd Small Cell Lung Carcinoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Pirotinib Hydrochloride KBP-5209 Phase 2 Clinical Shandong Xuanzhu Pharmaceutical Technology Co Ltd Solid tumours; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
PB-357 PB-357 Phase 1 Clinical Pfizer Inc Neoplasms Details
Sirotinib Maleate XZP-5491 Phase 1 Clinical Shandong Xuanzhu Pharmaceutical Technology Co Ltd Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
XZP-5209 XZP-5209 Phase 1 Clinical Xuanzhu (Shijiazhuang) Biotechnology Co Ltd Carcinoma, Non-Small-Cell Lung Details
Varlitinib Ditosylate SPS-4370; ASLAN-001; ARRY-334543; ARRY-543; QBT-01 Phase 3 Clinical Array Biopharma Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms Details
Larotinib Mesylate Z-650 Phase 3 Clinical Guangdong Dongyangguang Pharmaceutical Co Ltd Solid tumours; Esophageal Neoplasms; Pancreatic Neoplasms; Esophageal Squamous Cell Carcinoma Details
Tesevatinib XL-647; KD-020; KD-019; EXEL-7647 Phase 2 Clinical Exelixis Inc Glioblastoma; Neoplasms; Brain Neoplasms; Breast Neoplasms; Polycystic Kidney, Autosomal Dominant; Brain metastases; Polycystic Kidney, Autosomal Recessive; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Allitinib Tosylate AST-6; ALS-1306; AST-1306 Phase 2 Clinical Shanghai Allist Pharmaceutical Technology Co Ltd Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Neratinib (Fukang (Shanghai) Health Technology) CVL009; CVL-009 Phase 2 Clinical Solid tumours; Uterine Neoplasms; Carcinoma, Non-Small-Cell Lung Details
EO-1001 NT-113; APL-122 Phase 2 Clinical Edison Pharmaceuticals Inc Neoplasms Details
JRF-103 JRF103; JRF-103 Phase 2 Clinical Shenzhen Jinrui Foundation Biotechnology Co Ltd Solid tumours Details
FCN-411 FCN-411 Phase 2 Clinical Shanghai Fosun Pharmaceutical (Group) Co Ltd Small Cell Lung Carcinoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Pirotinib Hydrochloride KBP-5209 Phase 2 Clinical Shandong Xuanzhu Pharmaceutical Technology Co Ltd Solid tumours; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
PB-357 PB-357 Phase 1 Clinical Pfizer Inc Neoplasms Details
Sirotinib Maleate XZP-5491 Phase 1 Clinical Shandong Xuanzhu Pharmaceutical Technology Co Ltd Stomach Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung Details
XZP-5209 XZP-5209 Phase 1 Clinical Xuanzhu (Shijiazhuang) Biotechnology Co Ltd Carcinoma, Non-Small-Cell Lung Details

This web search service is supported by Google Inc.

totop

Nachricht schicken